About 5-hydroxytryptamine receptor 4
5-hydroxytryptamine receptor 4 (HTR4) is a protein
from Homo sapiens identified by UniProt accession
Q13639, 388 residues long.
MolForge cross-references it against 0 known binders and
236 disease associations.
Target properties
| Protein name | 5-hydroxytryptamine receptor 4 |
| UniProt accession | Q13639 |
| Gene | HTR4 |
| Organism | Homo sapiens |
| Length | 388 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (7)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (236)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.61
- Constipation · score 0.59
- post operative nausea and vomiting · score 0.58
- migraine disorder · score 0.57
- gastroparesis · score 0.56
- Chronic constipation · score 0.56
- Nausea and vomiting · score 0.54
- ileus · score 0.54
- Vomiting · score 0.54
- irritable bowel syndrome · score 0.54
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13639-F1 | alphafold | PREDICTED | 80.89 | — |
Amino-acid sequence (388 residues)
MDKLDANVSS EEGFGSVEKV VLLTFLSTVI LMAILGNLLV MVAVCWDRQL RKIKTNYFIV SLAFADLLVS VLVMPFGAIE LVQDIWIYGE VFCLVRTSLD VLLTTASIFH LCCISLDRYY AICCQPLVYR NKMTPLRIAL MLGGCWVIPT FISFLPIMQG WNNIGIIDLI EKRKFNQNSN STYCVFMVNK PYAITCSVVA FYIPFLLMVL AYYRIYVTAK EHAHQIQMLQ RAGASSESRP QSADQHSTHR MRTETKAAKT LCIIMGCFCL CWAPFFVTNI VDPFIDYTVP GQVWTAFLWL GYINSGLNPF LYAFLNKSFR RAFLIILCCD DERYRRPSIL GQTVPCSTTT INGSTHVLRD AVECGGQWES QCHPPATSPL VAAQPSDT
Explore 5-hydroxytryptamine receptor 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets